Get caught up with Contemporary OB/GYN's latest coverage from The Menopause Society Annual Meeting in San Diego, California.
|Articles|September 10, 2021
In case you missed it: Sept. 6 to Sept. 10
It was a busy week for the Contemporary OB/GYN® team.
Advertisement
This week's top articles included:
The power of social media in health care with Dr. Jennifer Lincoln
Endocrine-disrupting chemicals associated with uterine leiomyoma and endometriosis in US women
U.S. Department of Justice challenges Texas SB8
Getting started with office hysteroscopy
Advertisement
Related to this article
Misread Women’s Health Initiative data sidelined hormone therapy and menopause education, according to Mary Jane Minkin, MD, FACOG.
Susan Reed, MD, on the MsFLASH network's pooled findings, including nonhormonal therapies comparable to low-dose estradiol and CBT for sleep.
Late recurrence, high-risk features, and treatment failure can signal midlife night sweats aren’t menopause, according to Cheryl Cox Kinney, MD.
Hormone therapy was associated with more frequent, longer migraines in postmenopausal women, but not with greater severity or analgesic use.
JoAnn V. Pinkerton, MD, offers primary care counseling on elinzanetant's side effects and the early onset and continued relief of hot flashes.
Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.
Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Neurokinin receptor antagonists improve menopausal sleep disturbance
2
Stephanie Faubion, MD, on the first menopause therapy discussion
3
Red flags that point beyond menopause in patients with night sweats
4
How misread WHI data reshaped menopause care and training
5